US paus­es dis­tri­b­u­tion of GSK/Vir's Covid mAb not due to Omi­cron, but greater sup­ply of Eli Lil­ly mAbs

The US gov­ern­ment is shift­ing its dis­tri­b­u­tion of mAb in­fu­sions to fight the coro­n­avirus, de­cid­ing to go from sup­ply­ing tens of thou­sands of dos­es of Glax­o­SmithK­line and Vir’s mAb treat­ment sotro­vimab in re­cent months to ze­ro dos­es for the en­tire month of De­cem­ber.

That halt has led to spec­u­la­tion the gov­ern­ment was pri­or­i­tiz­ing the dis­tri­b­u­tion of Re­gen­eron mAb com­bo of casiriv­imab and imde­vimab and Eli Lil­ly’s com­bo of bam­lanivimab and ete­se­vimab be­cause both com­pa­nies have in­di­cat­ed that their in­fu­sions might not work as well against the Omi­cron vari­ant (when com­pared to Delta).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER